Developing innovative cancer treatments tackling GPCR mediated-immunosuppression
Discovery | Candidate | Preclinical | Phase I | Partner | |
---|---|---|---|---|---|
A2aR/A2bR antagonist (M1069) + |
Phase I
![]() |
||||
EP4 receptor antagonist (DT-9081) + | Phase I | ||||
Anti-CCR8 antibody (DT-7012) + | Candidate | ||||
PAR2 antagonist (DT-9045) + | Candidate | ||||
Undisclosed GPCR targets + | Discovery |
We build a high value pipeline focused on GPCRs to rearm immune system against tumors.